Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | — | — | — | — | — |
| Operating income | -$5.13M | -$13.1M | -$14.1M | -$16.1M | -$18.5M | -$36.9M | -$88.4M | -$43.0M | — | — |
| Net income | -$5.66M | -$13.1M | -$14.1M | -$16.0M | -$22.8M | -$34.5M | -$88.0M | -$117M | -$36.2M | -$45.6M |
| EPS (diluted) | -$2.46 | -$2.30 | -$1.56 | -$24.42 | -$15.72 | -$2.33 | -$6.16 | -$4.73 | -$0.66 | -$0.52 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.92M | -$14.9M | -$11.9M | -$13.9M | -$15.2M | -$28.9M | -$28.4M | -$39.5M | -$47.3M | -$62.3M |
| Capital expenditures | $9.00K | — | — | — | — | — | — | — | — | — |
| Free cash flow | -$4.93M | — | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.10M | $17.2M | $13.0M | $8.79M | $114M | $84.8M | $56.4M | $4.61M | $20.5M | $22.8M |
| Total assets | $1.20M | $20.9M | $17.0M | $10.9M | $197M | $171M | $92.8M | $89.1M | $177M | $169M |
| Total liabilities | $3.90M | $1.44M | $2.53M | $1.47M | $6.59M | $6.55M | $8.61M | $81.9M | $59.3M | $32.2M |
| Shareholders' equity | -$2.70M | $19.5M | $14.5M | $9.46M | $191M | $164M | $84.2M | -$48.5M | $62.4M | $81.1M |
| Retained earnings | -$14.4M | -$27.5M | -$41.6M | -$57.6M | -$80.4M | -$115M | -$203M | -$319M | -$356M | -$401M |
| Shares (wtd avg diluted) | 394K | 7.11M | 9.42M | 720K | 15.2M | 14.8M | 14.3M | 24.6M | 48.5M | 81.8M |
Every figure is extracted from Eledon Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.